SGLT2-inhibitors in Adult Patients With #Alport Syndrome #SGLT2i

#VisualAbstract by @krishnadoctor1

www.kireports.org/article/S2468-0249(26)02...

🎬I have built a small library of concise YouTube videos for people living with #T2D discussing:

🎯Positive lifestyle choices & #T2D
🎯Various aspects of #SGLT2i use including benefits, side-effects & sick day guidance
🎯UACR & #T2D with @kidneyresearchuk.org

Link in comments⬇️
@pharmrj.pharmsky.app

Urinary dipstick findings and UTI risk with SGLT2 inhibitors: a post hoc analysis of the CANVAS and CREDENCE trials AbstractBackground and Hypothesis. Despite established cardiorenal benefits, concerns about urinary tract infection (UTI) risk may limit SGLT2 inhibitor us

In a post-hoc analysis of 8,614 participants from CANVAS & CREDENCE trials, abnormal urinary leukocyte esterase & nitrite were associated with ⬆️ UTI risk. Canagliflozin did not ⬆️ UTI risk, including in those with abnormal urinary findings. #SGLT2i
🔗 doi.org/10.1093/ndt/...

Fundamental & Clinical Pharmacology: Vol 40, No 2 Click on the title to browse this issue

March issue now available!
#fundamental #clinical #pharmacology #statin #pharmacovigilance #addictovigilance #cannabis #ambroxol #dupilumab #buscopan #inflammation #cytokine #SGLT2i #heart #drug #repositioning #antinociceptive #SFPT @wileyhealth.bsky.social
onlinelibrary.wiley.com/toc/14728206...

Predictors of Discontinuation of Angiotensin Converting Enzyme Inhibitors Use Among Medicare Beneficiaries Using Sodium‐Glucose Cotransporter 2 Inhibitors Purpose Both angiotensin-converting enzyme inhibitors (ACEis) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) provide cardiovascular and renal benefits in Type 2 Diabetes (T2D) patients, sug.....

Happy to share my first first-author paper here :)
@ucsdpharmacy.bsky.social

onlinelibrary.wiley.com/doi/10.1002/...

#pharmacoepidemiology #ucsd #ucsandiego #hwsph #sspps #acei #sglt2i

RCT data showing that canagliflozin reduces myocardial fibrosis in high-risk #T2DM, providing imaging evidence for its cardioprotection #DiabetesResearch #SGLT2i

Canagliflozin attenuates CMR-quantified myocardial fibrosis in individuals with type 2 diabetes mellitus at high cardiovascular risk: a randomised open-label controlled trial - Diabetologia Aims/hypothesis We aimed to investigate canagliflozin’s effects on myocardial fibrosis, cardiac structure and function, and microcirculation in high-cardiovascular-risk type 2 diabetes mellitus throug...

Novel RCT: Canagliflozin reduces myocardial fibrosis (by CMR) in high-risk #T2DM, providing imaging evidence for its cardioprotection. A mechanism beyond glycaemic management. #SGLT2i #CardioDiabetes #HeartFailure #DiabetesResearch link.springer.com/article/10.1... 🔓

Glad to have contributed to this study, which has a very relevant clinical point: the BP lowering effect of SGLT2i of 4-5 mmHg is independent of renal function #nephsky #sglt2i

Effectiveness of Sodium–Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists on Diabetic Foot Disease: An Emulated Target Trial: Annals of Internal Medicine: Vol 0, No 0 Background: The effects of sodium–glucose cotransporter-2 inhibitors (SGLT-2is) on diabetic foot disease have been mixed in prior trials of SGLT-2is compared with placebo. The comparative risk for dia...

Usuarios recientes de SGLT2i tienen un riesgo modestamente menor de enfermedad del pie principalmente por un menor riesgo de neuropatía que los que usan GLP-1RA #foot #SGLT2i #GLP1RA www.acpjournals.org/doi/10.7326/...

#SGLT2i Inhibitors and Long-Term Outcomes After Acute Kidney Injury #AKI

#VisualAbstract by Abdul Qader

www.kireports.org/article/S2468-0249(25)00...

Sodium-Glucose Cotransporter-2 Inhibitors #SGLT2i and #Cardiorenal Events in #Nonalbuminuric Kidney Disease

#VisualAbstract by Augusto Cesar S Santos Jr

www.kireports.org/article/S2468-0249(25)00...

@cwhuang0824

Editorial: Special Report
SGLT-2 inhibition in pediatric CKD: advances, challenges, and opportunities

doi.org/10.1016/j.ki...

#NephSky #MedSky #OPenAccess #ckd #SGLT2i

Comparative Cardiovascular Outcomes of Dapagliflozin Versus Empagliflozin in Patients With Type 2 Diabetes: A Meta-Analysis Sodium-glucose co-transporter-2 (SGLT2) inhibitors have demonstrated significant cardiovascular benefits in patients with type 2 diabetes. However, head-to-head comparisons between dapagliflozin and e...

Battle of the SGLT2 Inhibitors: Dapagliflozin vs. Empagliflozin. Both are guideline pillars for Type 2 Diabetes & Heart Failure. But is one actually superior?

doi.org/10.7759/cureus.83449

#WeiPublications #CardioSky #Diabetes #MedSky #SGLT2i #Endocrinology #Cardiology #FOAMed

Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Preventing Heart Failure in Patients Receiving Anthracycline-Based Cancer Therapy: A Systematic Review and Meta-Analysis Anthracyclines are effective chemotherapeutic agents widely used to treat various cancers, but their use is limited by the risk of cardiotoxicity and heart failure. While strategies like dose reductio...

Chemo is effective but notorious for causing heart failure.

While SGLT2 inhibitors are proven heart-protectors in diabetes/HF, do they work as a "shield" for chemo patients?

doi.org/10.7759/cureus.60086

#WeiPublications #CardioOncology #SGLT2i #Chemo #HeartFailure #FOAMed

Sodium-glucose co-transporter 2 inhibition improves age-dependent kidney microvascular rarefaction

doi.org/10.1016/j.kint.2025.12.011

#OpenAccess #MedSky #NephSky #AfricanTurquoisekillifish #SGLT2i

A #FIDELITY Analysis on #Finerenone With #SGLT2i and #GLP1RA in CKD

#VisualAbstract by Cristina Popa

www.kireports.org/article/S2468-0249(25)00...

SGLT2 inhibitors in the prevention of nephrolithiasis: a comprehensive review | Giornale di Clinica Nefrologica e Dialisi

Kidney stones: could SGLT2 inhibitors help reduce risk? New comprehensive review.
journals.aboutscience.eu/index.php/gc...

International submissions welcome!

#Nephrolithiasis #SGLT2i
@aboutscience.bsky.social

SGLT2 inhibitors in polycystic kidney disease (PKD): current evidence and future perspectives | Giornale di Clinica Nefrologica e Dialisi

Beyond tolvaptan, what’s next for ADPKD? New review in GCND (Giornale di Clinica Nefrologica e Dialisi) on SGLT2 inhibitors in PKD.
International submission to the journal are welcome !!!

journals.aboutscience.eu/index.php/gc... #ADPKD #SGLT2i @aboutscience.bsky.social

🎊Our new research shows pre-transplant #GLP1RA + #SGLT2i therapy is associated with lower post-transplant mortality, fewer graft failures, and complications in organ transplant candidates with obesity and T2D. advanced.onlinelibrary.wiley.com/doi/full/10....

Fluid Balance in CKD: Empagliflozin Findings from SiRENA A video from William Shaffer (as part of ASN Kidney Week Highlights), posted on Nov 26, 2025.

Still interested in the mechanisms of #SGLT2i? I did a video with #Vumedi going through our study on the effects of empagliflozin on fluid and electrolyte balance. check it out: www.vumedi.com/video/fluid-...

Link for the studies 👇

#medsky #nephsky

Effectiveness of Pre‐Transplant Dual GLP‐1 Receptor Agonist and SGLT2 Inhibitor Therapy on All‐Cause Mortality in Organ Transplantation Candidates with Obesity and Type 2 Diabetes: a Target‐Trial Emul... This target trial emulation in solid organ transplant candidates with obesity and type 2 diabetes evaluates whether pre-transplant dual therapy with GLP-1 receptor agonists plus SGLT2 inhibitors is a....

Excited to share our new work using real world data and a target trial emulation to evaluate pre transplant dual therapy with #GLP1RA plus #SGLT2i in solid organ transplant candidates with #Obesity and #Type2Diabetes

advanced.onlinelibrary.wiley.com/doi/10.1002/...

Chronic kidney disease.

www.thelancet.com/action/showP...

@thelancet.com
#CardioSky #SGLT2i #NephSky

Important link to a @jama.com collaborative meta-analysis should you need to know more about the effects of #SGLT2i on kidney, CV, mortality and hospitalization outcomes in patients with and without diabetes, and at low levels of albuminuria: jamanetwork.com/journals/jam...

#SGLT2i might provide cardiorenal protection among older adults with dementia and diabetes compared with #DPP4i, but close monitoring needed due to greater susceptibility to #DKA #DiabetesResearch

DARE-AF & META-AF: Findings 🔎 on post-ablation strategies for patients w/ #AFib, including use of dapagliflozin in people w/out current indications for #SGLT2i & metformin compared w/ standard care in those w/ obesity/overweight but no #diabetes. https://bit.ly/4nJMbUc

#AHA25 #CardioSky #MedSky

When my 14 y/o Twitter account was banned in 2024 after a hack, I lost all #meded posts. But in #slideshare, I found my 2017 presentation, the year after I started my off-label use of #sglt2i in kidney disease. I'm glad I got most things right back then […]

[Original post on mastodon.social]

When my 14 y/o Twitter account was banned in 2024 after a hack, I lost all #meded posts. But in #slideshare, I found my 2017 presentation, the year after I started my off-label use of #sglt2i in kidney disease. I'm glad I got most things right back then
www.slideshare.net/chrisarg/sgl...

New results on combination therapy with SGLT2 inhibitors + GLP-1 RAs #DiabetesResearch #T2D #GLP-1RA #SGLT2i

@mikejohansenmd.medsky.social and myself said "class effect" 5 years ago when we put together a meta-analysis during the lockdowns
pmc.ncbi.nlm.nih.gov/articles/PMC...

My view of the economics of the #sglt2i from 4 years ago - worth considering the cost figure

pmc.ncbi.nlm.nih.gov/articles/PMC...

Almost all u need 2 know about the remarkable clinical effects of #SGLT2i on the kidney in a wide ranging IPD metaanalysis (covers effects by albuminuria, predicted eGFR dip and novel exploratory eGFR slope methods). Please do read it! @oxpop.bsky.social @martinlandray.bsky.social